Corbus Pharmaceuticals Holdings, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -0.02%177.140.7%$1156.72m
LLYEli Lilly & Co. -0.67%369.471.1%$1061.48m
MRKMerck & Co., Inc. 0.35%110.480.7%$1006.19m
PFEPfizer Inc. 2.52%51.510.9%$959.31m
ABBVAbbVie, Inc. 0.13%165.611.9%$896.70m
BMYBristol-Myers Squibb Co. -0.35%79.651.1%$739.40m
AZNAstraZeneca Plc 0.81%69.411.0%$357.25m
HZNPHorizon Therapeutics Plc 1.65%97.895.4%$291.17m
GSKGSK Plc -0.17%36.820.3%$250.64m
IDXXIDEXX Laboratories, Inc. 1.78%427.603.9%$194.80m
NVSNovartis AG -0.35%91.410.2%$187.82m
ALNYAlnylam Pharmaceuticals, Inc. 2.76%237.708.0%$172.78m
CTLTCatalent, Inc. -3.98%45.341.9%$163.63m
NVONovo Nordisk A/S 1.63%127.280.1%$154.53m
SNYSanofi -1.73%47.110.2%$135.70m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.